NEW YORK, NY--(Marketwire - Oct 27, 2011) - Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Bedford Report examines investing opportunities in the Biotechnology Industry and provides equity research on Human Genome Sciences, Inc. (NASDAQ: [ HGSI ]) and Xoma Ltd. (NASDAQ: [ XOMA ]). Access to the full company reports can be found at:

[ www.bedfordreport.com/HGSI ]

[ www.bedfordreport.com/XOMA ]

While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

The Bedford Report releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases. Earlier this month the company announced that it has been awarded a new contract for up to $28 million over five years to develop broad-spectrum antitoxins for the treatment of human botulism poisoning. The botulinum toxin, which causes botulism poisoning, is one of the most toxic poisons and is classified as a Class A, the highest level, bio-terror threat by the U.S. government.

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The company's loss for the third quarter widened to $88.4 million, or 45 cents per share, from $40.9 million, or 22 cents in the prior-year period. Revenue fell to $34 million from $50.8 million.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer